Cahill Represents Initial Purchaser in €825 Million Offering for Catalent Pharma Solutions, Inc.
Date: 03/02/20
Cahill represented the initial purchaser in connection with a Rule 144A European offering of €825,000,000 aggregate principal amount of 2.375% senior notes due 2028 by Catalent Pharma Solutions, Inc., a multinational corporation involved in technology and development for drugs, biologics and consumer health products. Proceeds from the offering were used to refinance existing indebtedness and for other general corporate purposes.